首页 > 最新文献

Advanced pharmaceutical bulletin最新文献

英文 中文
Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells. 利用GST融合系统在原核细胞中表达、纯化和表征功能性特杜葡肽。
IF 3.6 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 DOI: 10.34172/apb.2023.064
Ali Akbar Alizadeh, Saba Rasouli, Omid Jamshidi Kandjani, Salar Hemmati, Siavoush Dastmalchi

Purpose: Teduglutide is the first and only FDA-approved drug for long-term treatment of short bowel syndrome (SBS). The current study aimed to present an approach for production of teduglutide using recombinant DNA technology.

Methods: The coding gene for teduglutide was cloned into pGEX-2T vector, where coding sequence for factor Xa cleavage site was added between GST and teduglutide coding genes. The GST-teduglutide protein was overexpressed in E. coli BL21 (DE3) strain and affinity purified using glutathione sepharose affinity column.

Results: On-column proteolytic activity of factor Xa followed by size exclusion chromatography resulted in the pure teduglutide. Circular dichroism (CD) spectropolarimetry showed that the produced teduglutide folds into mainly α-helical structure (>50%), as expected. In mass spectroscopy analysis, the fragments of teduglutide resulted by cyanogen bromide cleavage as well as those expected theoretically due to mass fragmentation were identified. The functionality of the produced peptide was evaluated by measuring its proliferative effect on Caco2 intestinal epithelial cells, and the results indicated that produced teduglutide induces cell proliferation by 19±0.30 and 33±7.82 % at 1.21 and 3.64 µM concentrations, respectively, compared to untreated cells.

Conclusion: Teduglutide was successfully expressed and purified and its functionality and structural integrity were confirmed by in vitro experiments. We believe that the experimental-scale method presented in the current study can be useful for pilot-scale and also industrial-scale production of teduglutide.

目的:Teduglutide是fda批准的第一个也是唯一一个长期治疗短肠综合征(SBS)的药物。本研究旨在提出一种利用重组DNA技术生产特杜葡肽的方法。方法:将teduglutide编码基因克隆到pGEX-2T载体上,在GST与teduglutide编码基因之间添加Xa因子裂解位点编码序列。GST-teduglutide蛋白在大肠杆菌BL21 (DE3)中过表达,并通过谷胱甘肽sepharose亲和柱进行亲和纯化。结果:利用Xa因子的柱上蛋白水解活性,采用尺寸排斥层析法得到纯化的特杜葡肽。圆二色性(CD)光谱偏振分析表明,合成的teduglutide主要呈α-螺旋结构(>50%),与预期一致。在质谱分析中,确定了溴化氰裂解产生的片段和理论上预期的质量片段。通过测量其对Caco2肠上皮细胞的增殖作用来评估所制备肽的功能,结果表明,在1.21和3.64µM浓度下,所制备的teduglutide与未处理的细胞相比,分别诱导细胞增殖19±0.30%和33±7.82%。结论:成功地表达和纯化了Teduglutide,并通过体外实验证实了其功能和结构完整性。我们认为,本研究提出的实验规模方法可用于中试规模和工业规模的特杜葡肽生产。
{"title":"Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells.","authors":"Ali Akbar Alizadeh,&nbsp;Saba Rasouli,&nbsp;Omid Jamshidi Kandjani,&nbsp;Salar Hemmati,&nbsp;Siavoush Dastmalchi","doi":"10.34172/apb.2023.064","DOIUrl":"https://doi.org/10.34172/apb.2023.064","url":null,"abstract":"<p><strong>Purpose: </strong>Teduglutide is the first and only FDA-approved drug for long-term treatment of short bowel syndrome (SBS). The current study aimed to present an approach for production of teduglutide using recombinant DNA technology.</p><p><strong>Methods: </strong>The coding gene for teduglutide was cloned into pGEX-2T vector, where coding sequence for factor Xa cleavage site was added between GST and teduglutide coding genes. The GST-teduglutide protein was overexpressed in <i>E. coli</i> BL21 (DE3) strain and affinity purified using glutathione sepharose affinity column.</p><p><strong>Results: </strong>On-column proteolytic activity of factor Xa followed by size exclusion chromatography resulted in the pure teduglutide. Circular dichroism (CD) spectropolarimetry showed that the produced teduglutide folds into mainly α-helical structure (>50%), as expected. In mass spectroscopy analysis, the fragments of teduglutide resulted by cyanogen bromide cleavage as well as those expected theoretically due to mass fragmentation were identified. The functionality of the produced peptide was evaluated by measuring its proliferative effect on Caco2 intestinal epithelial cells, and the results indicated that produced teduglutide induces cell proliferation by 19±0.30 and 33±7.82 % at 1.21 and 3.64 µM concentrations, respectively, compared to untreated cells.</p><p><strong>Conclusion: </strong>Teduglutide was successfully expressed and purified and its functionality and structural integrity were confirmed by <i>in vitro</i> experiments. We believe that the experimental-scale method presented in the current study can be useful for pilot-scale and also industrial-scale production of teduglutide.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10121086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Designing Potent Anticancer Peptides by Aurein 1.2 Key Residues Mutation and Catenate Cell-Penetrating Peptide. 利用aurin 1.2关键残基突变和Catenate细胞穿透肽设计有效的抗癌肽。
IF 3.6 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 DOI: 10.34172/apb.2023.063
Hamta Salarpour Garnaie, Arman Shahabi, Mohammad Hossein Geranmayeh, Abolfazel Barzegar, Ahmad Yari Khosroushahi

Purpose: Aurein 1.2 (Aur) peptide is known for possessing anticancer characteristics devoid of conventional therapeutics side effects. For improving Aur peptide anticancer functionality, different anticancer peptides were constructed based on Aur peptide through targeting two separate strategies, including (1) sequence-based mutations and (2) adding a cell-penetrating peptide linker.

Methods: The study was approached by designing three different analogs of Aur, including (a) Aur mutant (Aurm), (b) Aur with N-terminal polyarginine linker (R5-Aur), and (c) Aurm with R5 (R5-Aurm). Computational molecular dynamics simulations clearly showed higher structural stability of R5-Aur and R5-Aurm compared to Aur, solely. The α-helical properties of R5-Aur and R5-Aurm were protected during 500 ns simulations in water solution while no such structural conservation was seen for Aur in silico.

Results: The results of the current study highlight response to one of the main challenges of cancer therapy through selective invasion of Aur to cancer cells without significant involvement of normal cells. This issue was confirmed by different assays, including: MTT assay, flow cytometry, qPCR, and nuclei morphological observations. Furthermore, this study intensifies exploiting in silico approaches for adjusting drug delivery. The results of different assessments on designed peptides reveal an anticancer activity pattern rising from Aur toward Aurm, and R5- Aur, consecutively.

Conclusion: The designed structure of Aur shows improved anticancer activity through molecular changes which makes it suggestable for anticancer therapies.

目的:aurin 1.2 (Aur)肽具有抗癌特性,且无常规治疗药物的副作用。为了提高Aur肽的抗癌功能,以Aur肽为基础,通过(1)基于序列的突变和(2)添加细胞穿透肽连接体两种不同的策略构建了不同的抗癌肽。方法:设计3种不同的Aur类似物,包括(a) Aur突变体(Aurm), (b) Aur与n端聚精氨酸连接体(R5-Aur), (c) Aurm与R5 (R5-Aurm)。计算分子动力学模拟清楚地表明,R5-Aur和R5-Aurm的结构稳定性高于Aur。R5-Aur和R5-Aurm的α-螺旋性质在500 ns的水溶液中得到保护,而Aur在硅中没有这种结构保护。结果:目前的研究结果强调了通过选择性侵袭癌细胞而不显著参与正常细胞来应对癌症治疗的主要挑战之一。不同的实验证实了这一问题,包括:MTT实验、流式细胞术、qPCR和细胞核形态学观察。此外,本研究加强了对调整药物递送的计算机方法的开发。对设计的多肽的不同评价结果显示,从Aur到Aurm, R5- Aur的抗癌活性依次上升。结论:所设计的Aur结构通过分子改变显示出较强的抗癌活性,可用于抗癌治疗。
{"title":"Designing Potent Anticancer Peptides by Aurein 1.2 Key Residues Mutation and Catenate Cell-Penetrating Peptide.","authors":"Hamta Salarpour Garnaie,&nbsp;Arman Shahabi,&nbsp;Mohammad Hossein Geranmayeh,&nbsp;Abolfazel Barzegar,&nbsp;Ahmad Yari Khosroushahi","doi":"10.34172/apb.2023.063","DOIUrl":"https://doi.org/10.34172/apb.2023.063","url":null,"abstract":"<p><strong>Purpose: </strong>Aurein 1.2 (Aur) peptide is known for possessing anticancer characteristics devoid of conventional therapeutics side effects. For improving Aur peptide anticancer functionality, different anticancer peptides were constructed based on Aur peptide through targeting two separate strategies, including (1) sequence-based mutations and (2) adding a cell-penetrating peptide linker.</p><p><strong>Methods: </strong>The study was approached by designing three different analogs of Aur, including (a) Aur mutant (Aur<sub>m</sub>), (b) Aur with N-terminal polyarginine linker (R5-Aur), and (c) Aur<sub>m</sub> with R5 (R5-Aur<sub>m</sub>). Computational molecular dynamics simulations clearly showed higher structural stability of R5-Aur and R5-Aur<sub>m</sub> compared to Aur, solely. The α-helical properties of R5-Aur and R5-Aur<sub>m</sub> were protected during 500 ns simulations in water solution while no such structural conservation was seen for Aur <i>in silico</i>.</p><p><strong>Results: </strong>The results of the current study highlight response to one of the main challenges of cancer therapy through selective invasion of Aur to cancer cells without significant involvement of normal cells. This issue was confirmed by different assays, including: MTT assay, flow cytometry, qPCR, and nuclei morphological observations. Furthermore, this study intensifies exploiting <i>in silico</i> approaches for adjusting drug delivery. The results of different assessments on designed peptides reveal an anticancer activity pattern rising from Aur toward Aur<sub>m</sub>, and R5- Aur, consecutively.</p><p><strong>Conclusion: </strong>The designed structure of Aur shows improved anticancer activity through molecular changes which makes it suggestable for anticancer therapies.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10121087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the Effect of Basic Amino Acids and Glucosamine on the Solubility of Ibuprofen and Piroxicam. 碱性氨基酸和氨基葡萄糖对布洛芬和吡洛昔康溶解度的影响。
IF 3.6 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 DOI: 10.34172/apb.2023.067
Hadi Valizadeh, Somayeh Mahdinloo, Negin Zakeri, Muhammad Sarfraz, Saeed Nezafat, Parvin Zakeri-Milani

Purpose: Poor aqueous solubility hampers the development of several compounds as pharmacological agents. Hence, preparing novel formulations with augmented absorption is a challenge in pharmaceutical industries. In this paper, we have examined the effect of basic amino acids including arginine (ARG), lysine (LYS), and glucosamine (GlucN) on the solubility of ibuprofen (IBU) and piroxicam (PXM) as drugs with limited solubility. We have also studied the effect of the dissolution media with the pH values 1.2 to 7.4.

Methods: The saturation shake-flask method was used for solubility studies in the presence of amino acids. Briefly, buffer solutions containing different concentrations of amino acids were prepared. Then, an excess amount of each drug with these buffers was shaken to reach equilibrium. After 48 hours, the upper phase was separated, and solubility was calculated by reading their UV-Vis absorbance.

Results: The results illustrated that amino acids increased solubility of both drugs with different ratios, which were pH and concentration-dependent. Solubility improved as the amount of amino acids went up, and this upward pattern was more robust with ARG than LYS. The presence of GlucN in citrate buffer significantly enhanced IBU solubility. The solubility of PXM in accompany of GlucN in water did not change significantly while in citrate buffer solubility enhanced specially at pH 6.

Conclusion: Overall, GlucN in citrate buffer and ARG in phosphate buffer could be introduced as the most suitable media for IBU and PXM solubility improvement, respectively.

目的:水溶性差阻碍了一些化合物作为药物的发展。因此,制备具有增强吸收的新型制剂是制药工业的一个挑战。本文研究了精氨酸(ARG)、赖氨酸(LYS)和葡萄糖胺(GlucN)等碱性氨基酸对布洛芬(IBU)和吡罗西康(PXM)溶解度的影响。我们还研究了pH值为1.2 ~ 7.4的溶解介质的影响。方法:采用饱和摇瓶法研究氨基酸存在下的溶解度。简单地说,制备了含有不同浓度氨基酸的缓冲溶液。然后,用这些缓冲液摇动过量的每种药物以达到平衡。48小时后,分离上相,通过读取其UV-Vis吸光度计算溶解度。结果:氨基酸对两种药物的溶解度均有不同比例的提高,且呈pH和浓度依赖性。溶解度随着氨基酸含量的增加而提高,而ARG的这种上升模式比LYS更强。柠檬酸缓冲液中葡聚糖的存在显著提高了IBU的溶解度。PXM与葡聚糖在水中的溶解度变化不明显,而在柠檬酸盐缓冲液中的溶解度在pH 6时增强。结论:总体而言,柠檬酸缓冲液中的葡糖苷和磷酸盐缓冲液中的ARG可分别作为改善IBU和PXM溶解度的最合适培养基。
{"title":"Investigating the Effect of Basic Amino Acids and Glucosamine on the Solubility of Ibuprofen and Piroxicam.","authors":"Hadi Valizadeh,&nbsp;Somayeh Mahdinloo,&nbsp;Negin Zakeri,&nbsp;Muhammad Sarfraz,&nbsp;Saeed Nezafat,&nbsp;Parvin Zakeri-Milani","doi":"10.34172/apb.2023.067","DOIUrl":"https://doi.org/10.34172/apb.2023.067","url":null,"abstract":"<p><strong>Purpose: </strong>Poor aqueous solubility hampers the development of several compounds as pharmacological agents. Hence, preparing novel formulations with augmented absorption is a challenge in pharmaceutical industries. In this paper, we have examined the effect of basic amino acids including arginine (ARG), lysine (LYS), and glucosamine (GlucN) on the solubility of ibuprofen (IBU) and piroxicam (PXM) as drugs with limited solubility. We have also studied the effect of the dissolution media with the pH values 1.2 to 7.4.</p><p><strong>Methods: </strong>The saturation shake-flask method was used for solubility studies in the presence of amino acids. Briefly, buffer solutions containing different concentrations of amino acids were prepared. Then, an excess amount of each drug with these buffers was shaken to reach equilibrium. After 48 hours, the upper phase was separated, and solubility was calculated by reading their UV-Vis absorbance.</p><p><strong>Results: </strong>The results illustrated that amino acids increased solubility of both drugs with different ratios, which were pH and concentration-dependent. Solubility improved as the amount of amino acids went up, and this upward pattern was more robust with ARG than LYS. The presence of GlucN in citrate buffer significantly enhanced IBU solubility. The solubility of PXM in accompany of GlucN in water did not change significantly while in citrate buffer solubility enhanced specially at pH 6.</p><p><strong>Conclusion: </strong>Overall, GlucN in citrate buffer and ARG in phosphate buffer could be introduced as the most suitable media for IBU and PXM solubility improvement, respectively.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10121088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preparation, Purification and Performance Evaluation of Polyclonal Antibody Against SARS-CoV-2 Produced in Rat. 大鼠抗SARS-CoV-2多克隆抗体的制备、纯化及性能评价
IF 3.6 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 DOI: 10.34172/apb.2023.059
Fatemeh Yaghoobizadeh, Mohammad Roayaei Ardakani, Mohammad Mehdi Ranjbar, Mohammad Khosravi, Hamid Galehdari

Purpose: Among all known human coronaviruses, some viruses (e.g., SARS-CoV-2) cause severe pneumonia or even death. With the regard to its spread and the importance of its rapid identification/treatment, and because pAbs are relatively cheap, able to bind to more sites on antigens and even neutralize them, this study was done for the production and purification of anti-SARS-CoV-2 polyclonal antibodies (pAb) in rats.

Methods: Viral antigen purification was performed by PEG/NaCl precipitation. The efficiency of the sucrose cushion method was also investigated to produce a purer antigen. Immunization was done and antibody purification was performed by ammonium sulfate precipitation (33%), dialysis, and ion-exchange chromatography. Western blotting and enzyme-linked immunosorbent assay (ELISA) were performed to verify the antibody specificity. All data were analyzed by SPSS software.

Results: The results showed that the amount of concentrated virus increased with the increase of PEG concentration. Moreover, the sucrose cushion method increased its purity. Besides, induction of immune response in rats for pAb production with high titers was reached via these antigens and ELISA/western blot results indicated a suitable antibody-antigen interaction. Additionally, it was shown that ion-exchange chromatography could be a suitable technique for IgG purification.

Conclusion: Herein, we presented a simple and cheap method for the purification of whole viral particles with relatively high quality. The results verified that these antigens could elicit a good immune response in the rat. The obtained pAbs showed a good specificity toward SARS-CoV-2 antigens. Accordingly, this study proposes a promising method for viral vaccine development.

目的:在所有已知的人类冠状病毒中,有些病毒(如SARS-CoV-2)会导致严重的肺炎甚至死亡。考虑到其广泛性和快速识别/治疗的重要性,并且由于pAb相对便宜,能够结合抗原上的更多位点甚至中和抗原,本研究进行了大鼠抗sars - cov -2多克隆抗体(pAb)的生产和纯化。方法:采用PEG/NaCl沉淀法纯化病毒抗原。还研究了蔗糖缓冲法的效率,以产生更纯净的抗原。免疫后用硫酸铵沉淀(33%)、透析、离子交换层析纯化抗体。采用Western blotting和酶联免疫吸附试验(ELISA)验证抗体特异性。所有数据均采用SPSS软件进行分析。结果:随着PEG浓度的增加,病毒浓缩量增加。此外,蔗糖缓冲法提高了其纯度。此外,通过这些抗原诱导大鼠产生高滴度的pAb免疫反应,ELISA/western blot结果表明抗体-抗原相互作用合适。此外,离子交换色谱法是一种纯化IgG的合适方法。结论:本文提出了一种简单、廉价、质量较高的病毒全粒纯化方法。结果证实,这些抗原能在大鼠体内引起良好的免疫反应。获得的pAbs对SARS-CoV-2抗原具有良好的特异性。因此,本研究为病毒疫苗的开发提供了一种有前景的方法。
{"title":"Preparation, Purification and Performance Evaluation of Polyclonal Antibody Against SARS-CoV-2 Produced in Rat.","authors":"Fatemeh Yaghoobizadeh,&nbsp;Mohammad Roayaei Ardakani,&nbsp;Mohammad Mehdi Ranjbar,&nbsp;Mohammad Khosravi,&nbsp;Hamid Galehdari","doi":"10.34172/apb.2023.059","DOIUrl":"https://doi.org/10.34172/apb.2023.059","url":null,"abstract":"<p><strong>Purpose: </strong>Among all known human coronaviruses, some viruses (e.g., SARS-CoV-2) cause severe pneumonia or even death. With the regard to its spread and the importance of its rapid identification/treatment, and because pAbs are relatively cheap, able to bind to more sites on antigens and even neutralize them, this study was done for the production and purification of anti-SARS-CoV-2 polyclonal antibodies (pAb) in rats.</p><p><strong>Methods: </strong>Viral antigen purification was performed by PEG/NaCl precipitation. The efficiency of the sucrose cushion method was also investigated to produce a purer antigen. Immunization was done and antibody purification was performed by ammonium sulfate precipitation (33%), dialysis, and ion-exchange chromatography. Western blotting and enzyme-linked immunosorbent assay (ELISA) were performed to verify the antibody specificity. All data were analyzed by SPSS software.</p><p><strong>Results: </strong>The results showed that the amount of concentrated virus increased with the increase of PEG concentration. Moreover, the sucrose cushion method increased its purity. Besides, induction of immune response in rats for pAb production with high titers was reached via these antigens and ELISA/western blot results indicated a suitable antibody-antigen interaction. Additionally, it was shown that ion-exchange chromatography could be a suitable technique for IgG purification.</p><p><strong>Conclusion: </strong>Herein, we presented a simple and cheap method for the purification of whole viral particles with relatively high quality. The results verified that these antigens could elicit a good immune response in the rat. The obtained pAbs showed a good specificity toward SARS-CoV-2 antigens. Accordingly, this study proposes a promising method for viral vaccine development.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10176428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MicroRNAs and Periodontal Disease: Helpful Therapeutic Targets? microrna与牙周病:有用的治疗靶点?
IF 3.6 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 DOI: 10.34172/apb.2023.048
Abdolhakim Palideh, Mostafa Vaghari-Tabari, Ali Nosrati Andevari, Durdi Qujeq, Zatollah Asemi, Forough Alemi, Hemmatollah Rouhani Otaghsara, Sona Rafieyan, Bahman Yousefi

Periodontal disease is the most common oral disease. This disease can be considered as an inflammatory disease. The immune response to bacteria accumulated in the gum line plays a key role in the pathogenesis of periodontal disease. In addition to immune cells, periodontal ligament cells and gingival epithelial cells are also involved in the pathogenesis of this disease. miRNAs which are small RNA molecules with around 22 nucleotides have a considerable relationship with the immune system affecting a wide range of immunological events. These small molecules are also in relation with periodontium tissues especially periodontal ligament cells. Extensive studies have been performed in recent years on the role of miRNAs in the pathogenesis of periodontal disease. In this review paper, we have reviewed the results of these studies and discussed the role of miRNAs in the immunopathogenesis of periodontal disease comprehensively. miRNAs play an important role in the pathogenesis of periodontal disease and maybe helpful therapeutic targets for the treatment of periodontal disease.

牙周病是最常见的口腔疾病。这种疾病可以认为是一种炎症性疾病。在牙周病的发病机制中,对积聚在牙龈线上的细菌的免疫反应起着关键作用。除免疫细胞外,牙周韧带细胞和牙龈上皮细胞也参与了本病的发病机制。mirna是一种大约有22个核苷酸的小RNA分子,与免疫系统有着相当大的关系,影响着广泛的免疫事件。这些小分子也与牙周组织特别是牙周韧带细胞有关。近年来,人们对mirna在牙周病发病机制中的作用进行了广泛的研究。在本文中,我们对这些研究结果进行了综述,并全面讨论了mirna在牙周病免疫发病机制中的作用。mirna在牙周病的发病机制中起着重要的作用,可能是治疗牙周病的有益靶点。
{"title":"MicroRNAs and Periodontal Disease: Helpful Therapeutic Targets?","authors":"Abdolhakim Palideh,&nbsp;Mostafa Vaghari-Tabari,&nbsp;Ali Nosrati Andevari,&nbsp;Durdi Qujeq,&nbsp;Zatollah Asemi,&nbsp;Forough Alemi,&nbsp;Hemmatollah Rouhani Otaghsara,&nbsp;Sona Rafieyan,&nbsp;Bahman Yousefi","doi":"10.34172/apb.2023.048","DOIUrl":"https://doi.org/10.34172/apb.2023.048","url":null,"abstract":"<p><p>Periodontal disease is the most common oral disease. This disease can be considered as an inflammatory disease. The immune response to bacteria accumulated in the gum line plays a key role in the pathogenesis of periodontal disease. In addition to immune cells, periodontal ligament cells and gingival epithelial cells are also involved in the pathogenesis of this disease. miRNAs which are small RNA molecules with around 22 nucleotides have a considerable relationship with the immune system affecting a wide range of immunological events. These small molecules are also in relation with periodontium tissues especially periodontal ligament cells. Extensive studies have been performed in recent years on the role of miRNAs in the pathogenesis of periodontal disease. In this review paper, we have reviewed the results of these studies and discussed the role of miRNAs in the immunopathogenesis of periodontal disease comprehensively. miRNAs play an important role in the pathogenesis of periodontal disease and maybe helpful therapeutic targets for the treatment of periodontal disease.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10176426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Virus-Specific T Cells: Promising Adoptive T Cell Therapy Against Infectious Diseases Following Hematopoietic Stem Cell Transplantation. 病毒特异性T细胞:造血干细胞移植后感染性疾病的有希望的过继T细胞疗法。
IF 3.6 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 DOI: 10.34172/apb.2023.046
Arsalan Jalili, Abbas Hajifathali, Mozhdeh Mohammadian, Ghazaleh Sankanian, Maryam Sayahinouri, Mahmoud Dehghani Ghorbi, Elham Roshandel, Nasser Aghdami

Hematopoietic stem cell transplantation (HSCT) is a life-saving therapy for various hematologic disorders. Due to the bone marrow suppression and its long recovery period, secondary infections, like cytomegalovirus (CMV), Epstein-Bar virus (EBV), and adenovirus (AdV), are the leading causes of morbidity and mortality in HSCT cases. Drug resistance to the antiviral pharmacotherapies makes researchers develop adoptive T cell therapies like virus-specific T cell therapy. These studies have faced major challenges such as finding the most effective T cell expansion methods, isolating the expected subtype, defining the functionality of the end-cell population, product quality control, and clinical complications after the injection. This review discusses the viral infections after HSCT, T cells characteristics during chronic viral infection, application of virus-specific T cells (VSTs) for refractory infections, standard methods for producing VSTs and their limitation, clinical experiences on VSTs, focusing on outcomes and side effects that can be helpful in decision-making for patients and further researches.

造血干细胞移植(HSCT)是一种挽救生命的治疗各种血液疾病。由于骨髓抑制和恢复期长,继发性感染,如巨细胞病毒(CMV)、eb病毒(EBV)和腺病毒(AdV),是HSCT病例发病和死亡的主要原因。对抗病毒药物疗法的耐药性促使研究人员开发出过继性T细胞疗法,如病毒特异性T细胞疗法。这些研究面临着重大挑战,如寻找最有效的T细胞扩增方法、分离预期亚型、确定终细胞群的功能、产品质量控制和注射后的临床并发症。本文综述了HSCT术后的病毒感染、慢性病毒感染过程中T细胞的特点、病毒特异性T细胞(VSTs)在难治性感染中的应用、产生VSTs的标准方法及其局限性、VSTs的临床应用经验,重点介绍了VSTs的结局和副作用,为患者的治疗决策和进一步的研究提供参考。
{"title":"Virus-Specific T Cells: Promising Adoptive T Cell Therapy Against Infectious Diseases Following Hematopoietic Stem Cell Transplantation.","authors":"Arsalan Jalili,&nbsp;Abbas Hajifathali,&nbsp;Mozhdeh Mohammadian,&nbsp;Ghazaleh Sankanian,&nbsp;Maryam Sayahinouri,&nbsp;Mahmoud Dehghani Ghorbi,&nbsp;Elham Roshandel,&nbsp;Nasser Aghdami","doi":"10.34172/apb.2023.046","DOIUrl":"https://doi.org/10.34172/apb.2023.046","url":null,"abstract":"<p><p>Hematopoietic stem cell transplantation (HSCT) is a life-saving therapy for various hematologic disorders. Due to the bone marrow suppression and its long recovery period, secondary infections, like cytomegalovirus (CMV), Epstein-Bar virus (EBV), and adenovirus (AdV), are the leading causes of morbidity and mortality in HSCT cases. Drug resistance to the antiviral pharmacotherapies makes researchers develop adoptive T cell therapies like virus-specific T cell therapy. These studies have faced major challenges such as finding the most effective T cell expansion methods, isolating the expected subtype, defining the functionality of the end-cell population, product quality control, and clinical complications after the injection. This review discusses the viral infections after HSCT, T cells characteristics during chronic viral infection, application of virus-specific T cells (VSTs) for refractory infections, standard methods for producing VSTs and their limitation, clinical experiences on VSTs, focusing on outcomes and side effects that can be helpful in decision-making for patients and further researches.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10112021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long and Short-term Metformin Consumption as a Potential Therapy to Prevent Complications of COVID-19. 长期和短期服用二甲双胍作为预防COVID-19并发症的潜在疗法
IF 3.6 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 DOI: 10.34172/apb.2023.066
Elnaz Shaseb, Saba Ghaffary, Alireza Garjani, Elnaz Zoghi, Nasrin Maleki Dizaji, Somaieh Soltani, Parvin Sarbakhsh, Mohammad Hossein Somi, Parya Valizadeh, Ali Taghizadieh, Masood Faghihdinevari, Mojtaba Varshochi, Behrooz Naghily, Zhinous Bayatmakoo, Parviz Saleh, Sepehr Taghizadeh, Mehdi Haghdoost, Hamid Owaysi, Fatemeh Ravanbakhsh Ghavghani, Mohammad Kazem Tarzamni, Rojin Moradi, Fateme Javan Ali Azar, Saeid Shabestari Khiabani, Ardavan Ghazanchaei, Sana Hamedani, Shahabeddin Hatefi

Purpose: The aim of the study is to evaluate the effect of metformin in complication improvement of hospitalized patients with COVID-19.

Methods: This was a randomized clinical trial that involved 189 patients with confirmed COVID-19 infection. Patients in the intervention group received metformin-500 mg twice daily. Patients who received metformin before admission were excluded from the control group. Patients who were discharged before taking at least 2000 mg of metformin were excluded from the study. Primary outcomes were vital signs, need for ICU admission, need for intubation, and mortality.

Results: Data showed that patients with diabetes with previous metformin in their regimen had lower percentages of ICU admission and death in comparison with patients without diabetes (11.3% vs. 26.1% (P=0.014) and 4.9% vs. 23.9% (P≤0.001), respectively). Admission time characteristics were the same for both groups except for diabetes and hyperlipidemia, which were significantly different between the two groups. Observations of naproxen consumption on endpoints, duration of hospitalization, and the levels of spO2 did not show any significant differences between the intervention and the control group. The adjusted OR for intubation in the intervention group versus the control group was 0.21 [95% CI, 0.04-0.99 (P=0.047)].

Conclusion: In this trial, metformin consumption had no effect on mortality and ICU admission rates in non-diabetic patients. However, metformin improved COVID-19 complications in diabetic patients who had been receiving metformin prior to COVID-19 infection, and it significantly lowered the intubation rates.

目的:评价二甲双胍在改善COVID-19住院患者并发症中的作用。方法:采用随机临床试验,纳入189例确诊的COVID-19感染患者。干预组患者接受二甲双胍-500毫克,每日两次。入院前接受二甲双胍治疗的患者排除在对照组之外。在服用至少2000毫克二甲双胍之前出院的患者被排除在研究之外。主要结局为生命体征、是否需要进入ICU、是否需要插管和死亡率。结果:数据显示,与非糖尿病患者相比,合并二甲双胍的糖尿病患者ICU住院率和死亡率较低(分别为11.3%对26.1% (P=0.014)和4.9%对23.9% (P≤0.001))。两组入院时间特征除糖尿病和高脂血症外均无差异,两组间差异有统计学意义。对终点、住院时间和spO2水平的观察显示,干预组和对照组之间没有任何显著差异。干预组与对照组插管调整OR为0.21 [95% CI, 0.04-0.99 (P=0.047)]。结论:在本试验中,二甲双胍的使用对非糖尿病患者的死亡率和ICU住院率没有影响。然而,二甲双胍改善了COVID-19感染前已接受二甲双胍治疗的糖尿病患者的COVID-19并发症,并显着降低了插管率。
{"title":"Long and Short-term Metformin Consumption as a Potential Therapy to Prevent Complications of COVID-19.","authors":"Elnaz Shaseb,&nbsp;Saba Ghaffary,&nbsp;Alireza Garjani,&nbsp;Elnaz Zoghi,&nbsp;Nasrin Maleki Dizaji,&nbsp;Somaieh Soltani,&nbsp;Parvin Sarbakhsh,&nbsp;Mohammad Hossein Somi,&nbsp;Parya Valizadeh,&nbsp;Ali Taghizadieh,&nbsp;Masood Faghihdinevari,&nbsp;Mojtaba Varshochi,&nbsp;Behrooz Naghily,&nbsp;Zhinous Bayatmakoo,&nbsp;Parviz Saleh,&nbsp;Sepehr Taghizadeh,&nbsp;Mehdi Haghdoost,&nbsp;Hamid Owaysi,&nbsp;Fatemeh Ravanbakhsh Ghavghani,&nbsp;Mohammad Kazem Tarzamni,&nbsp;Rojin Moradi,&nbsp;Fateme Javan Ali Azar,&nbsp;Saeid Shabestari Khiabani,&nbsp;Ardavan Ghazanchaei,&nbsp;Sana Hamedani,&nbsp;Shahabeddin Hatefi","doi":"10.34172/apb.2023.066","DOIUrl":"https://doi.org/10.34172/apb.2023.066","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of the study is to evaluate the effect of metformin in complication improvement of hospitalized patients with COVID-19.</p><p><strong>Methods: </strong>This was a randomized clinical trial that involved 189 patients with confirmed COVID-19 infection. Patients in the intervention group received metformin-500 mg twice daily. Patients who received metformin before admission were excluded from the control group. Patients who were discharged before taking at least 2000 mg of metformin were excluded from the study. Primary outcomes were vital signs, need for ICU admission, need for intubation, and mortality.</p><p><strong>Results: </strong>Data showed that patients with diabetes with previous metformin in their regimen had lower percentages of ICU admission and death in comparison with patients without diabetes (11.3% vs. 26.1% (<i>P</i>=0.014) and 4.9% vs. 23.9% (<i>P</i>≤0.001), respectively). Admission time characteristics were the same for both groups except for diabetes and hyperlipidemia, which were significantly different between the two groups. Observations of naproxen consumption on endpoints, duration of hospitalization, and the levels of spO<sub>2</sub> did not show any significant differences between the intervention and the control group. The adjusted OR for intubation in the intervention group versus the control group was 0.21 [95% CI, 0.04-0.99 (<i>P</i>=0.047)].</p><p><strong>Conclusion: </strong>In this trial, metformin consumption had no effect on mortality and ICU admission rates in non-diabetic patients. However, metformin improved COVID-19 complications in diabetic patients who had been receiving metformin prior to COVID-19 infection, and it significantly lowered the intubation rates.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10123432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Optimization of a Self-microemulsifying Drug Delivery System for Oral Administration of the Lipophilic Drug, Resveratrol: Enhanced Intestinal Permeability in Rat. 亲脂性药物白藜芦醇口服自微乳化给药系统的优化:增强大鼠肠道通透性。
IF 3.6 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 DOI: 10.34172/apb.2023.054
Shahla Mirzaeei, Negar Tahmasebi, Ziba Islambulchilar

Purpose: This study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to improve the solubility, release rate, and intestinal permeability of the drug.

Methods: The suitable oil, surfactant, and co-surfactant were chosen according to the drug solubility study. Utilizing the design of experiment (DoE) method, the pseudo-ternary phase diagram was plotted based on the droplet size. In vitro dissolution study and the single-pass intestinal perfusion were performed for the investigation of in vitro and in-situ permeability for drugs formulated as SMEDDS in rat intestine using High-Performance Liquid Chromatography.

Results: Castor oil, Cremophor® RH60, and PEG 1500 were selected as oil, surfactant, and co-surfactant. According to the pseudo-ternary phase diagram, nine formulations developed microemulsions with sizes ranging between 145-967 nm. Formulations passed the centrifuge and freeze-thaw stability tests. The optimum formulation possessed an almost 2.5-fold higher cumulative percentage of in vitro released resveratrol, in comparison to resveratrol aqueous suspension within 120 minutes. The results of the in-situ permeability study suggested a 2.6-fold higher intestinal permeability for optimum formulation than that of the resveratrol suspension.

Conclusion: SMEDDS can be considered suitable for the oral delivery of resveratrol according to the observed increased intestinal permeability, which could consequently enhance the bioavailability and therapeutic efficacy of the drug.

目的:在自微乳化给药系统(SMEDDS)中制备几乎不溶于水的抗氧化剂白藜芦醇,以提高药物的溶解度、释放速度和肠通透性。方法:根据药物溶解度研究,选择合适的油、表面活性剂和助表面活性剂。利用实验设计(DoE)方法,绘制了基于液滴尺寸的伪三元相图。采用高效液相色谱法进行大鼠体外溶出度研究和单次肠灌流法研究SMEDDS制剂在大鼠肠道内的体外和原位通透性。结果:选择蓖麻油、Cremophor®RH60、PEG 1500作为油脂、表面活性剂和助表面活性剂。根据伪三元相图,9个配方制备出了尺寸在145 ~ 967 nm之间的微乳液。配方通过了离心和冻融稳定性试验。与白藜芦醇水悬浮液相比,最佳配方在120分钟内体外释放白藜芦醇的累积百分比高出近2.5倍。原位渗透性研究结果表明,最佳配方的肠通透性比白藜芦醇混悬液高2.6倍。结论:SMEDDS可提高白藜芦醇的肠通透性,从而提高药物的生物利用度和治疗效果。
{"title":"Optimization of a Self-microemulsifying Drug Delivery System for Oral Administration of the Lipophilic Drug, Resveratrol: Enhanced Intestinal Permeability in Rat.","authors":"Shahla Mirzaeei,&nbsp;Negar Tahmasebi,&nbsp;Ziba Islambulchilar","doi":"10.34172/apb.2023.054","DOIUrl":"https://doi.org/10.34172/apb.2023.054","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to formulate Resveratrol, a practically water-insoluble antioxidant in a self-microemulsifying drug delivery system (SMEDDS) to improve the solubility, release rate, and intestinal permeability of the drug.</p><p><strong>Methods: </strong>The suitable oil, surfactant, and co-surfactant were chosen according to the drug solubility study. Utilizing the design of experiment (DoE) method, the pseudo-ternary phase diagram was plotted based on the droplet size. <i>In vitro</i> dissolution study and the single-pass intestinal perfusion were performed for the investigation of <i>in vitro</i> and <i>in-situ</i> permeability for drugs formulated as SMEDDS in rat intestine using High-Performance Liquid Chromatography.</p><p><strong>Results: </strong>Castor oil, Cremophor<sup>®</sup> RH60, and PEG 1500 were selected as oil, surfactant, and co-surfactant. According to the pseudo-ternary phase diagram, nine formulations developed microemulsions with sizes ranging between 145-967 nm. Formulations passed the centrifuge and freeze-thaw stability tests. The optimum formulation possessed an almost 2.5-fold higher cumulative percentage of <i>in vitro</i> released resveratrol, in comparison to resveratrol aqueous suspension within 120 minutes. The results of the <i>in-situ</i> permeability study suggested a 2.6-fold higher intestinal permeability for optimum formulation than that of the resveratrol suspension.</p><p><strong>Conclusion: </strong>SMEDDS can be considered suitable for the oral delivery of resveratrol according to the observed increased intestinal permeability, which could consequently enhance the bioavailability and therapeutic efficacy of the drug.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10121085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tau Protein Biosensors in the Diagnosis of Neurodegenerative Diseases. Tau蛋白生物传感器在神经退行性疾病诊断中的应用。
IF 3.6 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 DOI: 10.34172/apb.2023.061
Jafar Sadeghzadeh, Parviz Shahabi, Mehdi Farhoudi, Abbas Ebrahimi-Kalan, Ahmad Mobed, Kourosh Shahpasand

Tau protein plays a crucial role in diagnosing neurodegenerative diseases. However, performing an assay to detect tau protein on a nanoscale is a great challenge for early diagnosis of diseases. Enzyme-linked immunosorbent assay (ELISA), western-blotting, and molecular-based methods, e.g., PCR and real-time PCR, are the most widely used methods for detecting tau protein. These methods are subject to certain limitations: the need for advanced equipment, low sensitivity, and specificity, to name a few. With the above said, it is necessary to discover advanced and novel methods for monitoring tau protein. Counted among remarkable approaches adopted by researchers, biosensors can largely eliminate the difficulties and limitations associated with conventional methods. The main objective of the present study is to review the latest biosensors developed to detect the tau protein. Furthermore, the problems and limitations of conventional diagnosis methods were discussed in detail.

Tau蛋白在神经退行性疾病的诊断中起着至关重要的作用。然而,在纳米尺度上检测tau蛋白对疾病的早期诊断是一个巨大的挑战。酶联免疫吸附试验(ELISA)、western-blotting和基于分子的方法,如PCR和real-time PCR,是检测tau蛋白最广泛使用的方法。这些方法有一定的局限性:需要先进的设备,灵敏度低,特异性差,等等。因此,有必要寻找先进的、新颖的方法来监测tau蛋白。生物传感器在很大程度上消除了与传统方法相关的困难和限制,这是研究人员采用的重要方法之一。本研究的主要目的是综述最新开发的生物传感器检测tau蛋白。此外,还详细讨论了传统诊断方法存在的问题和局限性。
{"title":"Tau Protein Biosensors in the Diagnosis of Neurodegenerative Diseases.","authors":"Jafar Sadeghzadeh,&nbsp;Parviz Shahabi,&nbsp;Mehdi Farhoudi,&nbsp;Abbas Ebrahimi-Kalan,&nbsp;Ahmad Mobed,&nbsp;Kourosh Shahpasand","doi":"10.34172/apb.2023.061","DOIUrl":"https://doi.org/10.34172/apb.2023.061","url":null,"abstract":"<p><p>Tau protein plays a crucial role in diagnosing neurodegenerative diseases. However, performing an assay to detect tau protein on a nanoscale is a great challenge for early diagnosis of diseases. Enzyme-linked immunosorbent assay (ELISA), western-blotting, and molecular-based methods, e.g., PCR and real-time PCR, are the most widely used methods for detecting tau protein. These methods are subject to certain limitations: the need for advanced equipment, low sensitivity, and specificity, to name a few. With the above said, it is necessary to discover advanced and novel methods for monitoring tau protein. Counted among remarkable approaches adopted by researchers, biosensors can largely eliminate the difficulties and limitations associated with conventional methods. The main objective of the present study is to review the latest biosensors developed to detect the tau protein. Furthermore, the problems and limitations of conventional diagnosis methods were discussed in detail.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10123431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Combined Treatment of Dendrosomal-Curcumin and Daunorubicin Synergistically Inhibit Cell Proliferation, Migration and Induce Apoptosis in A549 Lung Cancer Cells. 树状体-姜黄素与柔红霉素联合治疗A549肺癌细胞协同抑制细胞增殖、迁移和诱导凋亡
IF 3.6 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-07-01 DOI: 10.34172/apb.2023.050
Seyed Sadegh Eslami, Davod Jafari, Abbas Ghotaslou, Moein Amoupour, Amir Asri Kojabad, Rasool Jafari, Navid Mousazadeh, Parastoo Tarighi, Majid Sadeghizadeh

Purpose: Chemotherapy drugs used to treat lung cancer are associated with drug resistance and severe side effects. There have been rising demands for new therapeutic candidates and novel approaches, including combination therapy. Here, we aimed to investigate the combinatorial effect of a dendrosomal formulation of curcumin (DNC) and daunorubicin (DNR) on the A549 lung cancer cell line.

Methods: We performed cytotoxicity, apoptosis, cell migration, colony-formation capacity, and gene expression analysis to interpret the mechanism of action for a combination of DNC and DNR on A549 cells.

Results: Our results revealed that the combination of DNC and DNR could synergistically inhibit the A549 cells' growth. This synergistic cytotoxicity was further approved by flow cytometry, migration assessment, colony-forming capacity and gene expression analysis. DNR combination with DNC resulted in increased apoptosis to necrosis ratio compared to DNR alone. In addition, the migration and colony-forming capacity were at the minimal range when DNC was combined with DNR. Combined treatment decreased the expression level of MDR-1, hTERT and Bcl-2 genes significantly. In addition, the ratio of Bax/Bcl2 gene expression significantly increased. Our analysis by free curcumin, dendrosomes and DNC also showed that dendrosomes do not have any significant cytotoxic effect on the A549 cells, suggesting that this carrier has a high potential for enhancing the curcumin's biological effects.

Conclusion: Our observations suggest that the DNC formulation of curcumin synergistically enhances the antineoplastic effect of DNR on the A549 cell line through the modulation of apoptosis/necrosis ratio, as well as Bax/Bcl2 ratio, MDR-1 and hTERT gene expression.

目的:用于治疗肺癌的化疗药物具有耐药性和严重的副作用。对新的候选治疗方法和新方法的需求不断增加,包括联合治疗。在这里,我们旨在研究姜黄素(DNC)和柔红霉素(DNR)在A549肺癌细胞系中的联合作用。方法:我们通过细胞毒性、细胞凋亡、细胞迁移、集落形成能力和基因表达分析来解释DNC和DNR联合对A549细胞的作用机制。结果:我们的研究结果显示,DNC和DNR联合使用可以协同抑制A549细胞的生长。流式细胞术、迁移评估、集落形成能力和基因表达分析进一步证实了这种协同细胞毒性。与单独DNR相比,DNR联合DNC导致细胞凋亡坏死比增加。此外,DNC与DNR联合使用时,其迁移能力和集落形成能力处于最小范围。联合治疗可显著降低MDR-1、hTERT和Bcl-2基因的表达水平。Bax/Bcl2基因表达比例显著升高。我们对游离姜黄素、树突体和DNC的分析也表明,树突体对A549细胞没有明显的细胞毒作用,表明该载体具有增强姜黄素生物学效应的巨大潜力。结论:姜黄素DNC制剂通过调节A549细胞的凋亡/坏死比、Bax/Bcl2比、MDR-1和hTERT基因表达,协同增强DNR对A549细胞的抗肿瘤作用。
{"title":"Combined Treatment of Dendrosomal-Curcumin and Daunorubicin Synergistically Inhibit Cell Proliferation, Migration and Induce Apoptosis in A549 Lung Cancer Cells.","authors":"Seyed Sadegh Eslami,&nbsp;Davod Jafari,&nbsp;Abbas Ghotaslou,&nbsp;Moein Amoupour,&nbsp;Amir Asri Kojabad,&nbsp;Rasool Jafari,&nbsp;Navid Mousazadeh,&nbsp;Parastoo Tarighi,&nbsp;Majid Sadeghizadeh","doi":"10.34172/apb.2023.050","DOIUrl":"https://doi.org/10.34172/apb.2023.050","url":null,"abstract":"<p><strong>Purpose: </strong>Chemotherapy drugs used to treat lung cancer are associated with drug resistance and severe side effects. There have been rising demands for new therapeutic candidates and novel approaches, including combination therapy. Here, we aimed to investigate the combinatorial effect of a dendrosomal formulation of curcumin (DNC) and daunorubicin (DNR) on the A549 lung cancer cell line.</p><p><strong>Methods: </strong>We performed cytotoxicity, apoptosis, cell migration, colony-formation capacity, and gene expression analysis to interpret the mechanism of action for a combination of DNC and DNR on A549 cells.</p><p><strong>Results: </strong>Our results revealed that the combination of DNC and DNR could synergistically inhibit the A549 cells' growth. This synergistic cytotoxicity was further approved by flow cytometry, migration assessment, colony-forming capacity and gene expression analysis. DNR combination with DNC resulted in increased apoptosis to necrosis ratio compared to DNR alone. In addition, the migration and colony-forming capacity were at the minimal range when DNC was combined with DNR. Combined treatment decreased the expression level of <i>MDR-1, hTERT</i> and <i>Bcl-2</i> genes significantly. In addition, the ratio of <i>Bax/Bcl2</i> gene expression significantly increased. Our analysis by free curcumin, dendrosomes and DNC also showed that dendrosomes do not have any significant cytotoxic effect on the A549 cells, suggesting that this carrier has a high potential for enhancing the curcumin's biological effects.</p><p><strong>Conclusion: </strong>Our observations suggest that the DNC formulation of curcumin synergistically enhances the antineoplastic effect of DNR on the A549 cell line through the modulation of apoptosis/necrosis ratio, as well as <i>Bax/Bcl2</i> ratio, <i>MDR-1</i> and <i>hTERT</i> gene expression.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10176423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Advanced pharmaceutical bulletin
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1